165 related articles for article (PubMed ID: 38031139)
1. EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.
Li B; Zhou Q; Wan Q; Qiao X; Chen S; Zhou J; Wuxiao Z; Luo L; Ng SB; Li J; Chng WJ
Clin Epigenetics; 2023 Nov; 15(1):187. PubMed ID: 38031139
[TBL] [Abstract][Full Text] [Related]
2. MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.
Li B; Yan J; Phyu T; Fan S; Chung TH; Mustafa N; Lin B; Wang L; Eichhorn PJA; Goh BC; Ng SB; Kappei D; Chng WJ
Blood; 2019 Dec; 134(23):2046-2058. PubMed ID: 31434700
[TBL] [Abstract][Full Text] [Related]
3. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.
Liu J; Liang L; Huang S; Nong L; Li D; Zhang B; Li T
Hum Pathol; 2019 Jan; 83():166-176. PubMed ID: 30218753
[TBL] [Abstract][Full Text] [Related]
4. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
5. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
Feng Y; Jing C; Yu X; Cao X; Xu C
Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
[TBL] [Abstract][Full Text] [Related]
6. Establishment and comprehensive analysis of a new human cell line (NK-NJ) with NK-cell characteristics established from extranodal natural killer cell lymphoma/leukemia.
Liang JH; Wang WT; Du KX; Xing TY; Wang Y; Wang H; Liu L; Guo R; Shao Y; Liang J; Li Y; Shen HR; Wang L; Li JY; Xu W
Hum Cell; 2023 Mar; 36(2):835-846. PubMed ID: 36520345
[TBL] [Abstract][Full Text] [Related]
7. Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.
Mundy-Bosse BL; Weigel C; Wu YZ; Abdelbaky S; Youssef Y; Casas SB; Polley N; Ernst G; Young KA; McConnell KK; Nalin AP; Wu KG; Broughton M; Lordo MR; Altynova E; Hegewisch-Solloa E; Enriquez-Vera DY; Dueñas D; Barrionuevo C; Yu SC; Saleem A; Suarez CJ; Briercheck EL; Molina-Kirsch H; Loughran TP; Weichenhan D; Plass C; Reneau JC; Mace EM; Gamboa FV; Weinstock DM; Natkunam Y; Caligiuri MA; Mishra A; Porcu P; Baiocchi RA; Brammer JE; Freud AG; Oakes CC
Blood Cancer Discov; 2022 Mar; 3(2):154-169. PubMed ID: 35247900
[TBL] [Abstract][Full Text] [Related]
8. CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion.
Jin X; Yang C; Fan P; Xiao J; Zhang W; Zhan S; Liu T; Wang D; Wu H
J Biol Chem; 2017 Apr; 292(15):6269-6280. PubMed ID: 28242758
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathogenic pathways in extranodal NK/T cell lymphoma.
de Mel S; Hue SS; Jeyasekharan AD; Chng WJ; Ng SB
J Hematol Oncol; 2019 Apr; 12(1):33. PubMed ID: 30935402
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma.
Tian XP; Zhang YC; Lin NJ; Wang L; Li ZH; Guo HG; Ma SY; An MJ; Yang J; Hong YH; Wang XH; Zhou H; Li YJ; Rao HL; Li M; Hu SX; Lin TY; Li ZM; Huang H; Liang Y; Xia ZJ; Lv Y; Liu YY; Duan ZH; Chen QY; Wang JN; Cai J; Xie Y; Ong CK; Liu F; Liu YY; Yan Z; Huang L; Tao R; Li WY; Huang HQ; Cai QQ
Cell Rep Med; 2023 Feb; 4(2):100859. PubMed ID: 36812892
[TBL] [Abstract][Full Text] [Related]
11. TRIP12 functions as an E3 ubiquitin ligase of APP-BP1.
Park Y; Yoon SK; Yoon JB
Biochem Biophys Res Commun; 2008 Sep; 374(2):294-8. PubMed ID: 18627766
[TBL] [Abstract][Full Text] [Related]
12. EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma.
Lee JY; Kim JH; Bang H; Cho J; Ko YH; Kim SJ; Kim WS
Sci Rep; 2021 May; 11(1):10342. PubMed ID: 33990633
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site.
Lee WJ; Jung JM; Won CH; Chang SE; Choi JH; Chan Moon K; Park CS; Huh J; Lee MW
J Am Acad Dermatol; 2014 Jun; 70(6):1002-9. PubMed ID: 24629518
[TBL] [Abstract][Full Text] [Related]
14. Trip12 is an E3 ubiquitin ligase for USP7/HAUSP involved in the DNA damage response.
Liu X; Yang X; Li Y; Zhao S; Li C; Ma P; Mao B
FEBS Lett; 2016 Dec; 590(23):4213-4222. PubMed ID: 27800609
[TBL] [Abstract][Full Text] [Related]
15. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological study of pulmonary extranodal nature killer/T-cell lymphoma, nasal type and literature review.
Ding W; Wang J; Zhao S; Yang Q; Sun H; Yan J; Gao L; Yao W; Zhang W; Liu W
Pathol Res Pract; 2015 Jul; 211(7):544-9. PubMed ID: 25953340
[TBL] [Abstract][Full Text] [Related]
17. Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).
Haverkos BM; Coleman C; Gru AA; Pan Z; Brammer J; Rochford R; Mishra A; Oakes CC; Baiocchi RA; Freud AG; Porcu P
Discov Med; 2017 Mar; 23(126):189-199. PubMed ID: 28472613
[TBL] [Abstract][Full Text] [Related]
18. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
[TBL] [Abstract][Full Text] [Related]
19. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.
Rong QX; Wang F; Guo ZX; Hu Y; An SN; Luo M; Zhang H; Wu SC; Huang HQ; Fu LW
Mol Cancer; 2021 May; 20(1):80. PubMed ID: 34051805
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.
He C; Liu B; Wang HY; Wu L; Zhao G; Huang C; Liu Y; Shan B; Liu L
BMC Cancer; 2022 Oct; 22(1):1100. PubMed ID: 36303126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
